Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338767 · ClinicalTrials.gov registry record · Phase 2
Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy
A Phase 2 study of Depression and HIV Infections, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00338767: Completed Phase 2 study of Depression and HIV Infections, sponsored by Massachusetts General Hospital.
NCT00338767 is a Phase 2 study of Depression and HIV Infections that has completed, run by Massachusetts General Hospital. The registered enrollment target is 150 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00338767, a Phase 2 study of Depression and HIV Infections, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of directly observed therapy plus antidepressant medication in improving adherence to antiretroviral drug therapy among HIV-infected homeless and marginally housed people with depression.
Conditions Studied
Interventions
- DRUG Fluoxetine
- BEHAVIORAL Directly Observed Therapy (DOT)
Study Locations (1)
California
- UCSF Market Street Study Site - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00338767 record still lists
NCT00338767 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Fluoxetine is the first listed.
NCT00338767 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00338767 about?
NCT00338767 is a clinical study titled "Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy". This study will evaluate the effectiveness of directly observed therapy plus antidepressant medication in improving adherence to antiretroviral drug therapy among HIV-infected homeless and marginally housed people with depression.
What is the current status of trial NCT00338767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2001-01. Estimated completion is 2006-08.
What conditions does trial NCT00338767 study?
This clinical trial studies the following conditions: Depression, HIV Infections.
What interventions are being tested in trial NCT00338767?
The interventions under investigation include: Fluoxetine (DRUG), Directly Observed Therapy (DOT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00338767?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00338767 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00338767's enrollment target sits among peer trials
150 249th of 679 higher than 416 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia